J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
The U.S. Food and Drug Administration has expanded the approval for Johnson & Johnson's nasal spray Spravato to allow its ...
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a ...
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato, to treat adults with ...
Emerging research in mental health is showing how little we know and thus how much work needs to be done, including in how ...
S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.
Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion. The deal includes Caplyta, a treatment for schizophrenia and bipolar depression, along with a pipeline focused on ...
Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system ...
Republicans are poised to take control of the House of Representatives this month by the narrowest seat margin in nearly 100 ...
Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...